Coldstream Laboratories announces manager of technology transfer
Sholto Maclean takes newly created role at Kentucky firm
In this newly created position, Maclean will work with Coldstream's pharmaceutical development team to scale up processes for sterile liquid and lyophilised drug products for manufacturing in the company's sterile facility.
Maclean has more than 20 years of experience in parenteral processing, sterile product development, lyophilisation development and aseptic manufacturing. Most recently, he was a lyophilisation/technology transfer consultant for a major pharmaceutical company. Previous roles include positions at GlaxoSmithKline and DSM Pharmaceuticals.
Coldstream Laboratories operates the only sterile pharmaceutical manufacturing facility in Kentucky.
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
From bespoke to scalable: closing the manufacturing gap in advanced therapeutics
Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics
Manufacturing
Piramal Pharma Solutions announces partnership with Botanix to support drug substance development
Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra. Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis. Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra